Wharton Business Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$798K Hold
665
0.03% 90
2026
Q1
$612K Hold
665
0.02% 90
2025
Q4
$715K Hold
665
0.03% 89
2025
Q3
$507K Hold
665
0.02% 100
2025
Q2
$518K Hold
665
0.02% 98
2025
Q1
$549K Buy
665
+60
+10% +$49.9K 0.02% 95
2024
Q4
$467K Hold
605
0.02% 99
2024
Q3
$536K Hold
605
0.02% 98
2024
Q2
$548K Buy
605
+30
+5% +$24K 0.03% 92
2024
Q1
$447K Hold
575
0.02% 101
2023
Q4
$335K Hold
575
0.02% 106
2023
Q3
$309K Hold
575
0.02% 115
2023
Q2
$270K Buy
+575
New +$241K 0.02% 115
2023
Q1
Sell
-575
Closed -$210K 140
2022
Q4
$210K Buy
+575
New +$204K 0.01% 134

Other funds holding LLY

Wharton Business Group's LLY Position: Q2 2026 in Review

Wharton Business Group held its Eli Lilly (LLY) position steady in Q2 2026 at 665 shares worth $798K. The position accounts for 0.03% of the portfolio, ranked #90.

Wharton Business Group first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Wharton Business Group held 665 shares of Eli Lilly worth $798K as of Q2 2026.
  • Wharton Business Group left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.03% of Wharton Business Group's portfolio in Q2 2026, its #90 holding.
  • Wharton Business Group first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Wharton Business Group's 13F filing for Q2 2026, filed 10 Aug 2026.